Important Safety Information
Full Prescribing Information
Visit Peer2Peer Clinical Education
About
OMIDRIA
CHOOSE FDA-APPROVED OMIDRIA FOR PROVEN SAFETY
OMIDRIA demonstrated ocular adverse reaction rates similar to placebo¹
*Combined clinical trial results from 3 randomized, placebo-controlled studies. These adverse event rates may not reflect the rates observed in practice.
Ocular adverse reactions reported by ≥2% of subjects*
OMIDRIA demonstrated ocular adverse reaction rates similar to placebo as reported in the combined clinical trial results from 3 randomized, placebo-controlled studies.¹
Ocular Events
OMIDRIA (n=459)
Placebo (n=462)
Anterior chamber inflammation
Increased intraocular pressure
Posterior capsule opacification
Eye irritation
Foreign body sensation in eye
111 (24%)
20 (4%)
18 (4%)
9 (2%)
8 (2%)
102 (22%)
15 (3%)
16 (4%)
6 (1%)
11 (2%)
REFERENCE:
-
OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023.
Indications and Usage
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Important Safety Information
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Indications and Usage
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
Important Safety Information
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.